Calamos Advisors’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Calamos Advisors’s Portfolio LSBPW Stock Details LSBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-146,040	Closed	-$5.32K	–	1019
2025 Q2	$5.32K	Hold	146,040	–	–	﹤0.01%	895
2025 Q1	$6.03K	Hold	146,040	–	–	﹤0.01%	877
2024 Q4	$14.5K	Hold	146,040	–	–	﹤0.01%	860
2024 Q3	$7.21K	Hold	146,040	–	–	﹤0.01%	894
2024 Q2	$9.95K	Hold	146,040	–	–	﹤0.01%	889
2024 Q1	$7.45K	Hold	146,040	–	–	﹤0.01%	907
2023 Q4	$3.96K	Hold	146,040	–	–	﹤0.01%	886
2023 Q3	$5.11K	Hold	146,040	–	–	﹤0.01%	906
2023 Q2	$6.86K	Hold	146,040	–	–	﹤0.01%	941
2023 Q1	$22.7K	Buy	+146,040	New	+$22.1K	﹤0.01%	993

Other funds holding LSBPW

HIM

HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Calamos Advisors's LSBPW Position: Q3 2025 in Review

Calamos Advisors sold out of LakeShore Biopharma Warrants (LSBPW) in Q3 2025, closing a stake of 146,040 shares — an estimated $5.32K sold.

Calamos Advisors first reported a position in LSBPW in Q1 2023 and held it in 10 quarters. The position peaked at $22.7K in Q1 2023. 3 funds tracked by Wall St. Rank hold LSBPW as of Q3 2025.

Calamos Advisors reported no remaining LakeShore Biopharma Warrants position as of Q3 2025 after selling out during the quarter.
Calamos Advisors sold 146,040 LakeShore Biopharma Warrants shares in Q3 2025, an estimated $5.32K.
Calamos Advisors first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 10 quarters.
Calamos Advisors's LakeShore Biopharma Warrants position peaked at $22.7K in Q1 2023.
3 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q3 2025.

Based on Calamos Advisors's 13F filing for Q3 2025, filed 20 Oct 2025.